Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrogen SCHEMBL28276545 | 0.96 | CYP3A4 (0.59) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL1771537 | 0.89 | CYP3A4 (0.56) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL30873107 | 0.89 | CYP3A4 (0.56) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL460989 | 0.88 | HTT (0.66) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL2062178 | 0.86 | CYP3A4 (0.56) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL2566274 | 0.86 | CYP3A4 (0.53) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL12781601 | 0.85 | CYP3A4 (0.55) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL1520431 | 0.85 | GAA (0.59) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL29893629 | 0.85 | GAA (0.59) | CYP3A4TSHRTDP1ALDH1A1POLB | |
| SCHEMBL3596469 | 0.84 | CYP3A4 (0.54) | CYP3A4TSHRTDP1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430967-A | High-dispersity permanent orange RN and preparation method and application thereof | 济宁阳光化学有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-109678727-A | A kind of method of microchannel nitration reaction synthesis 2- ethyl -5- nitroaniline | 深圳市华先医药科技有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-109384725-A | A kind of method of microchannel diazo reaction synthesis 3- methyl -6- nitro -1H- indazole | 深圳市华先医药科技有限公司 | 2019-02-26 | — | — | CN | claimed |
| US-9714254-B2 | Anilino podophyllin derivative having antitumor activity, method for preparation thereof, and use thereof | HUBEI UNIVERSITY OF TECHNOLOGY (CN) | 2017-07-25 | — | — | US | claimed |
| US-20160289242-A1 | ANILINO PODOPHYLLIN DERIVATIVE HAVING ANTITUMOR ACTIVITY, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | HUBEI UNIVERSITY OF TECHNOLOGY (CN) | 2016-10-06 | — | — | US | claimed |
| CN-220803176-U | Microchannel structure for continuous synthesis reaction | 杭州莫洛特化学科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117430967-A | High-dispersity permanent orange RN and preparation method and application thereof | 济宁阳光化学有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-114394935-A | Improved preparation method of pazopanib key intermediate | 南京亿华药业有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114394935-A | Improved preparation method of pazopanib key intermediate | 南京亿华药业有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114230558-A | Preparation method of pexaparib hydrochloride impurity | 海南鑫开源医药科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-112538073-A | Preparation method of pazopanib intermediate | 上海天慈中商药业有限公司 | 2021-03-23 | — | — | CN | disclosed |
| WO-2020238220-A1 | METHOD FOR PREPARING PAZOPANIB HYDROCHLORIDE | 济南爱思医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0425345-B1 | Keratinic fibres dyeing process with amino-indoles, composition and use devices | OREAL (FR) | 1994-09-14 | — | — | EP | disclosed |
| US-5254135-A | Applying indole dye, developing with oxidizing system | L'OREAL (FR) | 1993-10-19 | — | — | US | disclosed |
| CN-1051669-A | With the method for amino indole dyeing keratinous fibres, compositions and facilities and equipments | OREAL (FR) | 1991-05-29 | — | — | CN | disclosed |
| EP-0002041-A1 | Processes for synthesizing bisazomethine-bisazo pigments | CIBA-GEIGY AG (CH) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289242-A1 | ANILINO PODOPHYLLIN DERIVATIVE HAVING ANTITUMOR ACTIVITY, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | MLN, DAO, DCPS | CYP3A4 106/4885TSHR 4488/4885TDP1 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.